20/15 Visioneers’ Post

New and very exciting results from the RUBY 2 trial in patients with endometrial cancer ✨

#Cancer is one of the leading cause of death worlwide, bit even with the big investiments there are still gigantic #diaparities in care. As an #oncologist working in the #pharmaceuticalindustry I take as a victory every time we have a new class or drug discovery, because I know this means many will benefit from it; but it's even greater when a new treatment is available at public systems around the world, benefiting even more people. I'm proud to say that at Ipsen we fight daily to bring innovation to a broader number of people in need. #worldcancerday #oncology #closethecaregap

Through Onco-PDO®, you will gain an additional insight into your tumor’s response against a panel of approved drugs. Hence, the data from your Onco-PDO® test report will allow your doctor to design a more personalized cancer treatment that will increase the positive outcomes. #PrecisionOncology #Livingsciences #CancerTreatment

This entry of our MAI Mindset column, Lee Blansett, MBA, summarizes the third part of a study by HMP Market Access Insights which examined the influence and impact pathways have on oncologists’ treatment decisions. "HMP MAI found that oncology pathways, particularly those implemented by providers, can influence oncologists’ treat­ment decisions for patients with cancer. The impact of path­ways varied depending on the source (provider vs payer), tumor type, and oncologist’s initial preference," said Blansett. Read the full report here: https://lnkd.in/dAAVAXYZ #JournalOfClinicalPathways #MarketAccessInsights #MAIMindset #HMP #Oncology #Payers #DecisionMaking

The Evolving Role of Imaging and Trial Design in Oncology Drug Development Advanced Clinical Outsourcing-Pharma https://lnkd.in/ePhHtSuK #ClinicalTrials #CancerResearch #OncoDaily #Oncology #Cancer #Health #Medicine

Fantastic insights from Dr. Hope Rugo, USA, during the Pfizer symposium on "Navigating Through CDK4/6 Inhibitors Clinical Trial and Real World-Based Evidence", only at #APBCS2024! #APBCS2024 #BreastCancer #MSD #symposium #faculty #speaker #panelist #breastoncology #registration #SABCS #Bali #indonesia #BaliSummit #BreastCancer #oncology #treatment #healthcare #cancercare #oncologyresearch #registration #CPE #CME

New ENGOT Trial results on #endometrialcancer 🙌 The RUBY 2 Trial demonstrated a statistically significant and clinically meaningful improvement in PFS of patients with primary advanced or recurrent endometrial cancer when treated with dostarlimab in combination with standard of care carboplatin/paclitaxel followed by dostarlimab and niraparib compared to chemotherapy alone. The results were presented by Mansoor Mirza, the trial’s global clinical investigator, this weekend at #SGO2024 in San Diego 🇺🇸. Read more 👉https://buff.ly/3PmN5Ys #SGOmtg #clinicaltrial #gynonc #ENGOT #Rubytrial #oncology

PD-L1 testing is the cornerstone in determining the suitability of PD-1/PD-L1 inhibitors. Now that PROphetNSCLC™ is available in 49 states, the PROphet® result can be used in addition to the PD-L1 score, which has been shown in clinical evaluations to stratify patient outcomes. Further stratification of your patient population makes it easier to guide your treatment decisions within the guidelines, which helps answer the clinical question you’re facing: ICI alone or in combination with chemotherapy? #immunotherapy #ICI #NSCLC #lungcancer #oncology

"Exciting news! Introducing Abirabuzz (abiraterone 500 mg) from Jasgur Life Science – a breakthrough in prostate cancer treatment. With its advanced formulation and Jasgur Life Science's commitment to excellence, Abirabuzz is set to redefine standards in oncology care. Join us as we pave the way for better patient outcomes. #Abirabuzz #JasgurLifeScience #ProstateCancer #MedicalInnovation"

ONCOLOGY NEWS: Virtual reality sessions lessen cancer pain in clinical trial https://lnkd.in/eYjkFBG2 #virtualreality #emergingtech #oncologynews #cancerpain #cancerpainmanagement